Eisai and Biogen Win EU Approval for Leqembi in Early Alzheimer’s Disease
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...
Eisai Co., Ltd. (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) jointly announced that they have...
China-based Jiangsu Wuzhong Pharmaceutical Group Corp. (SHA: 600200) has disclosed a potential forced delisting from...
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its antibody-drug conjugate (ADC) BL-M09D1...
Tianjin Pharmaceutical Da Ren Tang Group Co., Ltd. (SHA: 600329), a traditional Chinese medicine (TCM)...
China-based Akeso Biopharma (HKG: 9926) has entered into a clinical collaboration with Virogin Biotech Co.,...
China-based genomics testing company Berry Genomics (SHE: 000710) has entered into a project achievement translation...
President Donald Trump issued a new Executive Order aimed at reducing drug prices for American...
Switzerland-based skin care specialist Galderma officially launched Sculptra in China this week, marking the first...
Chengdu-based Easton Pharmaceutical Co., Ltd (SHA: 688513) has announced preliminary statistical analysis results from the...
US medical device giant Edwards Lifesciences Corporation (NYSE: EW) has announced that it has received...
Beijing-based biopharmaceutical company InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that China’s Center for...
The National Health Commission (NHC) has issued the “List of Basic Service Packages for Family...
China-based Kossel Medtech (Suzhou) Co., Ltd., a vascular interventional medical device platform company, has entered...
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...
Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...
The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...